...
首页> 外文期刊>Macromolecular bioscience >A potential nanomedicine consisting of heparin-Loaded Polysaccharide Nanocarriers for the Treatment of Asthma
【24h】

A potential nanomedicine consisting of heparin-Loaded Polysaccharide Nanocarriers for the Treatment of Asthma

机译:一种潜在的纳米药物,由载有肝素的多糖纳米载体组成,可用于治疗哮喘

获取原文
获取原文并翻译 | 示例
           

摘要

A new nanomedicine consisting of chitosan/carboxymethyl-β-cyclodextrin loaded with unfractioned or low-molecular-weight heparin is described and its potential in asthma treatment is evaluated. The nanoparticles are prepared by ionotropic gelation showing a size that between 221 and 729nm with a positive zeta potential. The drug association efficiency is higher than 70%. Developed nanosystems are stable in Hank's balanced salt solution at pH=6.4, releasing the drug slowly. Ex vivo assays show that nanocarriers lead to an improvement of heparin preventing mast cell degranulation. These results agree with the effective cellular internalization of the fluorescently labeled nanocarriers, and suggest these nanomedicines as promising formulations for asthma treatment.
机译:描述了一种由壳聚糖/羧甲基-β-环糊精负载未分级或低分子量肝素组成的新型纳米药物,并评估了其在哮喘治疗中的潜力。通过离子凝胶法制备纳米颗粒,其显示在221和729nm之间的大小,具有正的ζ电势。药物缔合效率高于70%。发达的纳米系统在Hank的平衡盐溶液中(pH = 6.4)稳定,可缓慢释放药物。离体试验表明,纳米载体可改善肝素,防止肥大细胞脱粒。这些结果与荧光标记的纳米载体的有效细胞内在化一致,并表明这些纳米药物是用于哮喘治疗的有前途的制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号